Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Free Cash Flow (2016 - 2025)

Lexaria Bioscience's Free Cash Flow history spans 11 years, with the latest figure at -$984098.0 for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 64.22% year-over-year to -$984098.0; the TTM value through Nov 2025 reached -$8.7 million, down 32.53%, while the annual FY2025 figure was -$10.5 million, 109.42% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$984098.0 at Lexaria Bioscience, up from -$2.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$619614.0 in Q1 2024 and bottomed at -$3.6 million in Q2 2025.
  • The 5-year median for Free Cash Flow is -$1.3 million (2022), against an average of -$1.5 million.
  • The largest YoY upside for Free Cash Flow was 64.22% in 2025 against a maximum downside of 183.08% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$1.2 million in 2021, then dropped by 4.73% to -$1.3 million in 2022, then grew by 6.65% to -$1.2 million in 2023, then tumbled by 132.78% to -$2.8 million in 2024, then soared by 64.22% to -$984098.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Free Cash Flow are -$984098.0 (Q4 2025), -$2.6 million (Q3 2025), and -$3.6 million (Q2 2025).